Characteristics | IRD (n = 48) | Non-IRD (n = 40) | p Value |
---|---|---|---|
Age, years, mean ± SD | 66 ± 10 | 66 ± 11 | 0.85 |
Male sex, n (%) | 28 (58) | 27 (68) | 0.45 |
Duration of CAD, months, median (IQR) | 24 (81) | 32 (119) | 0.39 |
History of myocardial infarction, n (%) | 30 (63) | 19 (48) | 0.17 |
Number of myocardial infarctions, mean ± SD | 0.8 ± 0.9 | 0.6 ± 0.8 | 0.28 |
NYHA class, mean ± SD | 2.9 ± 0.7 | 2.6 ± 0.6 | 0.04 |
Number of coronary arteries with significant stenosis, mean ± SD | 2.7 ± 0.6 | 2.6 ± 0.7 | 0.44 |
Acute coronary syndrome, n (%) | 12 (25) | 10 (25) | 0.90 |
Left ventricular ejection fraction, mean ± SD | 64 ± 12 | 65 ± 11 | 0.52 |
Previous heart surgery, n (%) | 1 (2.1) | 0 (0) | 0.73 |
Positive family history of CAD,a n (%) | 33 (69) | 31 (78) | 0.41 |
C-reactive protein, mg/L, median (IQR) | 4.9 (10.5) | 2.1 (2.6) | <0.001 |
ESR, mm/h, median (IQR) | 23 (28) | 13 (17) | 0.003 |
Troponin I, ng/ml, median (IQR) | 0.06 (0.11) | 0.01 (0.04) | 0.01 |
Body mass index, kg/m2, mean ± SD | 25 ± 4 | 26 ± 3 | 0.58 |
Hypertension, n (%) | 28 (58) | 20 (50) | 0.46 |
Current smoker, n (%) | 13 (27) | 7 (18) | 0.26 |
Previous smoking, n (%) | 18 (38) | 18 (45) | 0.45 |
Diabetes mellitus, n (%) | 6 (13) | 5 (13) | 0.87 |
Hypercholesterolemia, n (%) | 40 (83) | 36 (90) | 0.45 |
Acetylsalicylic acid, n (%) | 43 (90) | 35 (88) | 0.88 |
ACE inhibitors, n (%) | 15 (31) | 12 (30) | 0.91 |
Statins, n (%) | 37 (77) | 32 (80) | 0.70 |
Beta blockers, n (%) | 36 (75) | 31 (78) | 0.71 |
Disease-modifying antirheumatic drugs,b n (%) | 16 (33) | 0 (0) | <0.001 |
Systemic glucocorticosteroids, n (%) | 19 (40) | 0 (0) | <0.001 |
Nonsteroidal anti-inflammatory drugs, n (%) | 6 (13) | 0 (0) | 0.018 |
Cyclooxygenase 2 selective inhibitors, n (%) | 8 (17) | 0 (0) | 0.004 |
Duration of IRD, years, mean ± SD | 17 ± 12 | NA | NA |
Patient’s global assessment of disease activity,c mean ± SD | 3.1 ± 2.5 | NA | NA |
Physician’s global assessment of disease activity,c mean ± SD | 1.4 ± 1.3 | NA | NA |